Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2020 - 2025)

Insight Molecular Diagnostics' Total Non-Current Liabilities history spans 6 years, with the latest figure at $9.2 million for Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities fell 16.01% year-over-year to $9.2 million; the TTM value through Sep 2025 reached $9.2 million, down 16.01%, while the annual FY2024 figure was $9.6 million, 79.59% down from the prior year.
  • Total Non-Current Liabilities for Q3 2025 was $9.2 million at Insight Molecular Diagnostics, up from $8.5 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $87.3 million in Q4 2021 and bottomed at $8.5 million in Q2 2025.
  • The 5-year median for Total Non-Current Liabilities is $23.4 million (2022), against an average of $32.9 million.
  • The largest annual shift saw Total Non-Current Liabilities surged 489.13% in 2021 before it plummeted 81.99% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $87.3 million in 2021, then plummeted by 79.5% to $17.9 million in 2022, then soared by 164.14% to $47.3 million in 2023, then tumbled by 79.59% to $9.6 million in 2024, then decreased by 4.72% to $9.2 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Total Non-Current Liabilities are $9.2 million (Q3 2025), $8.5 million (Q2 2025), and $11.8 million (Q1 2025).